MarketCap
Facebook
X
Telegram
Centogene N.V. Cost of Revenue | CNTG
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.3 M | 27.7 M | 28.7 M | 35.3 M | 26 M | 19.9 M | 14.9 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.3 M | 14.9 M | 26.3 M |
Quarterly Cost of Revenue Centogene N.V.
| 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.3 M | 15.7 M | 27.7 M | - | - | 6.45 M | 28.7 M | 35.6 M | 43.8 M | 6.21 M | 35.3 M | 26.1 M | 6.82 M | 7.02 M | - | 6.64 M | 6.11 M | 6.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.8 M | 6.11 M | 19.3 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
4.09 M | $ 2.05 | 0.84 % | $ 5.98 M |  USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.45 | 0.96 % | $ 7.9 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
137 M | $ 15.83 | 0.62 % | $ 166 M |  China |
 |
Bioventus
BVS
|
180 M | $ 13.52 | 2.97 % | $ 901 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 69.85 | 4.02 % | $ 3.72 B | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
71 M | $ 36.65 | 3.07 % | $ 1.06 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 232.22 | 0.07 % | $ 25.8 B | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 221.21 | 3.34 % | $ 158 B | USA |
 |
DarioHealth Corp.
DRIO
|
9.69 M | $ 5.8 | 1.24 % | $ 23.1 M |  Israel |
 |
DexCom
DXCM
|
1.86 B | $ 86.9 | 1.8 % | $ 33.9 B | USA |
 |
Fulgent Genetics
FLGT
|
192 M | $ 22.45 | 4.52 % | $ 691 M | USA |
 |
Guardant Health
GH
|
349 M | $ 187.22 | 5.3 % | $ 23.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
6.08 B | $ 168.33 | 3.88 % | $ 13.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.64 B | $ 527.07 | 1.67 % | $ 42.4 B | USA |
 |
Illumina
ILMN
|
1.47 B | $ 293.69 | 7.56 % | $ 45.5 B | USA |
 |
IQVIA Holdings
IQV
|
10.9 B | $ 266.09 | 3.05 % | $ 45.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 308.65 | 0.05 % | $ 25.7 B | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 100.19 | 0.23 % | $ 6.76 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.58 | 0.88 % | $ 424 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 6.31 | 4.13 % | $ 4.97 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 19.13 | 3.57 % | $ 2.45 B | USA |
 |
Neogen Corporation
NEOG
|
462 M | $ 13.01 | 7.08 % | $ 2.83 B | USA |
 |
Natera
NTRA
|
158 M | $ 425.64 | 3.73 % | $ 58.2 B | USA |
 |
OPKO Health
OPK
|
401 M | $ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 2.87 | 12.99 % | $ 861 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 23.91 | 0.04 % | $ 22.7 B |  Niderland |
 |
Precipio
PRPO
|
13.3 M | $ 24.0 | 3.76 % | $ 38.5 M | USA |
 |
Personalis
PSNL
|
53.9 M | $ 16.4 | 0.74 % | $ 1.46 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | $ 45.79 | 2.34 % | $ 9.95 B | Niderland |
 |
RadNet
RDNT
|
1 B | $ 70.63 | 1.0 % | $ 5.31 B | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 10.31 | 4.35 % | $ 430 M | USA |
 |
Sotera Health Company
SHC
|
518 M | $ 18.55 | 1.81 % | $ 5.27 B | USA |
 |
Neuronetics
STIM
|
76.8 M | $ 2.2 | 1.85 % | $ 145 M | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 205.0 | 8.66 % | $ 12.3 B | USA |
 |
Waters Corporation
WAT
|
363 M | $ 440.12 | 3.51 % | $ 26.2 B | USA |
 |
Exagen
XGN
|
27.8 M | $ 8.46 | 3.55 % | $ 182 M | USA |
 |
Syneos Health
SYNH
|
4.14 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
Renalytix AI plc
RNLX
|
2.13 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |